Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

13 Apr 2021

Abstract excerpt

Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A key ambition of the CARAMBA project is to provide clinical proof-of-concept for virus-free CAR gene transfer using advanced Sleeping Beauty (SB) transposon technology....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33846552
DOI: 10.1038/s41434-021-00254-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myelomaPMID 33846552Read ↗

Genomic Analyses of SLAMF7 CAR-T Cells Manufactured by <i>Sleeping Beauty</i> Transposon Gene Transfer for Immunotherapy of Multiple MyelomaSemantic proximity Read ↗

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?Semantic proximity Read ↗

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancesSemantic proximity Read ↗

A meta-analysis on safety and efficacy of CD19 directed CAR T-cells generated using sleeping beauty transposon systemSemantic proximity Read ↗

The Past, Present, and Future of Non-Viral CAR T CellsSemantic proximity Read ↗

Going non-viral: theSleeping Beautytransposon system breaks on through to the clinical sideSemantic proximity Read ↗

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesSemantic proximity Read ↗

Comparison of Lentiviral and Sleeping Beauty Mediated αβ T Cell Receptor Gene TransferSemantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

A new approach to gene therapy using <i>Sleeping Beauty</i> to genetically modify clinical‐grade T cells to target <scp>CD</scp>19Semantic proximity Read ↗

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Semantic proximity Read ↗

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.